Needham keeps Hold on ResMed over GLP-1 risks
Alpha Vantage · Investing.com · · AI-summarised by FinFlash
Needham reiterated its Hold rating on ResMed despite the medical device maker beating revenue and EPS expectations in its first fiscal quarter of 2027. The analyst cited risks from new drug therapies and Philips' eventual return to the U.S. market. ResMed plans to return over Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context